Will Host Conference Call and Webcast on Wednesday, November 10, 2004 at4:30 p.m. EST
SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders, today announced that it will report third quarter2004 financial results on Wednesday, November 10, 2004, after the U.S.financial markets close.
ACADIA will host a conference call and webcast on Wednesday, November 10,2004 at 4:30 p.m. EST to discuss financial results for the third quarter endedSeptember 30, 2004. Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer,will also provide an update on the Company's progress.
The conference call may be accessed by dialing 800-901-5247 forparticipants from the United States or Canada and 617-786-4501 forinternational callers (reference participant passcode 92945056). Theconference call will also be webcast live on ACADIA's website atwww.acadia-pharm.com, under the investor relations section, and will bearchived there until November 24, 2004.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of novel treatmentsfor central nervous system disorders. ACADIA currently has five drug programsin clinical and preclinical development directed at large unmet medical needsand major commercial markets, including Parkinson's disease, schizophrenia,chronic pain, and glaucoma. Using its proprietary drug discovery platform,ACADIA has discovered all of the drug candidates in its product pipeline.ACADIA's corporate headquarters and biology research facilities are located inSan Diego, California and its chemistry research facilities are located nearCopenhagen, Denmark.
For further information, please contact Thomas H. Aasen, Vice Presidentand Chief Financial Officer of ACADIA Pharmaceuticals Inc., +1-858-558-2871.